5-Amino-1MQ is a research compound that inhibits an enzyme called nicotinamide N-methyltransferase (NNMT).

What is NNMT?

NNMT is an enzyme involved in energy metabolism. Higher NNMT activity has been associated in research with:

Obesity
Insulin resistance
Type 2 diabetes
Fatty liver disease
Some cancers
Age-related metabolic dysfunction

The theory is that inhibiting NNMT may allow cells to use energy more efficiently and improve metabolic health.

What is 5-Amino-1MQ studied for?

Researchers have investigated it for several potential effects:

1. Fat loss (most common area of research)

Increased fat burning
Reduced fat storage
Decreased body fat in obese animal models
Preservation of lean muscle during weight loss

2. Improved insulin sensitivity
Animal studies suggest it may improve glucose metabolism and reduce insulin resistance.

3. Fatty liver
Some research suggests NNMT inhibition may reduce liver fat accumulation.

4. Cellular energy
May increase NAD+ availability and improve mitochondrial function, although this is still being investigated.

5. Aging research
Because NNMT influences NAD+ metabolism, it has attracted interest in longevity research, but there is no evidence that it extends lifespan in humans.

Human evidence

There are currently very limited human clinical data. Most claims made online about dramatic fat loss are based on:

Mouse studies
Cell culture research
Anecdotal reports

There is not enough evidence to know:

The most effective dose
Long-term safety
Side effects over months or years
Drug interactions

Common research stacks

Among researchers and experimental users, 5-Amino-1MQ is often combined with compounds aimed at body composition:

Compound	Reason for stacking
Tirzepatide	Appetite suppression plus potential increase in fat oxidation
Retatrutide	Similar rationale with greater weight-loss potential
Cagrilintide	Additional appetite reduction
Tesamorelin	Investigated for reducing visceral fat while preserving muscle
MOTS-c	Experimental mitochondrial support and insulin sensitivity
AOD-9604	Experimental fat metabolism research
L-Carnitine	Fatty acid transport into mitochondria
NAD+ precursors (NMN or NR)	Theoretical support for NAD+ metabolism, though benefits with 5-Amino-1MQ are unproven

Does it pair well with GLP-1 medications?

The combination that receives the most attention is:

Tirzepatide + 5-Amino-1MQ
- Tirzepatide primarily reduces food intake.
- 5-Amino-1MQ is hypothesized to increase energy expenditure and fat utilization.
- There are no high-quality human trials showing that the combination is superior to tirzepatide alone.

Bottom line

5-Amino-1MQ is an experimental NNMT inhibitor being studied primarily for obesity, insulin resistance, fatty liver disease, and metabolic health. The scientific rationale is promising, but the evidence is still largely preclinical. It is commonly stacked in research settings with GLP-1 receptor agonists (such as Tirzepatide or Retatrutide), MOTS-c, Tesamorelin, and other body-composition-focused compounds, but the safety and effectiveness of these combinations have not been established in controlled human studies.

Your cart is empty